Reviewing Elekta AB (publ) (OTCMKTS:EKTAY) & Fortrea (NASDAQ:FTRE)

Fortrea (NASDAQ:FTREGet Free Report) and Elekta AB (publ) (OTCMKTS:EKTAYGet Free Report) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Fortrea and Elekta AB (publ), as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea 1 2 5 1 2.67
Elekta AB (publ) 2 0 0 0 1.00

Fortrea currently has a consensus price target of $35.57, indicating a potential upside of 32.19%. Given Fortrea’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortrea is more favorable than Elekta AB (publ).

Profitability

This table compares Fortrea and Elekta AB (publ)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortrea -4.11% 4.76% 1.87%
Elekta AB (publ) 7.88% 15.16% 5.01%

Valuation and Earnings

This table compares Fortrea and Elekta AB (publ)’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fortrea $3.11 billion 0.77 -$3.40 million ($1.39) -19.36
Elekta AB (publ) $1.61 billion 1.84 $90.25 million $0.36 21.53

Elekta AB (publ) has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Elekta AB (publ), indicating that it is currently the more affordable of the two stocks.

Summary

Elekta AB (publ) beats Fortrea on 7 of the 12 factors compared between the two stocks.

About Fortrea

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

About Elekta AB (publ)

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.